Bicitra ( XXXX ) and @entity1769 in outpatient anesthesia for prophylaxis against aspiration pneumonitis.

@entity1 @entity4958 @entity1769
To evaluate the effect of Bicitra (Willen Drug Company, Baltimore, Maryland), a commercial preparation of @entity4958 and @entity1769 , on gastric contents 150 elective outpatients allocated into six groups with 25 @entity1 in each group were studied. @entity1 in Group 1 served as controls. @entity1 in Groups 2, 3, 5, and 6 received Bicitra, po, either 15 ml (Groups 2 and 5) or 30 ml (Groups 3 and 6). In addition, @entity1 in Groups 5 and 6 also received @entity1769 10 mg, iv; Group 4 @entity1 received @entity1769 10 mg, iv. Eighty-eight per cent of @entity1 in the control group had a gastric pH less than or equal to 2.5, while 36% had a gastric content volume greater than or equal to 25 ml with pH less than or equal to 2.5. Bicitra, 15 ml and 30 ml, po, increased mean gastric pH and decreased the proportion of @entity1 with a gastric pH less than or equal to 2.5 to 32 and 16%, respectively, in Groups 2 and 3. However, Bicitra 15 ml and 30 ml, increased the mean gastric volume in Group 3 and also increased the proportion of @entity1 with a gastric volume greater than or equal to 25 ml to 56% in Group 2 and 84% in Group 3. The addition of @entity1769 10 mg, iv, to Bicitra reduced the proportion of @entity1 with a gastric volume greater than or equal to 25 ml in Groups 5 and 6 to 28 and 36%, respectively. @entity1769 (Group 6) independently reduced mean gastric volume (15.6 ml vs. 32.7 ml) and the proportion of @entity1 with a gastric volume greater than or equal to 25 ml (20% vs. 36%). Bicitra and @entity1769 combination significantly reduced the proportion of @entity1 with gastric contents greater than or equal to 25 ml with pH less than or equal to 2.5.
